Asthma Medication Receives New Warning

No Thumbnail Available

Links to Files

https://ezproxy.stevenson.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=107811912&site=eds-live&scope=site

Permanent Link

http://dx.doi.org/10.1097/01.NAJ.0000459621.92420.e0
 http://hdl.handle.net/11603/5651

Collections

Stevenson University Faculty and Staff Works

Author/Creator

Author/Creator ORCID

Date

2015-01

Type of Work

journal articles
Text

Department

Sandra R. Berman School of Nursing and Health Professions

Program

Nursing

Citation of Original Publication

Aschenbrenner, D. S. (2015). Asthma medication receives new warning. AJN American Journal Of Nursing, 115(1), 22-23. doi:10.1097/01.NAJ.0000459621.92420.e0

Rights

Subjects

Abstract

The labeling of omalizumab (Xolair), a drug used to treat allergic asthma, now carries a warning that its use may slightly increase the risk of cardiovascular complications. The drug may also pose an increased risk of inducing cancer.